Companies › Marea Therapeutics
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MAR001 APOC3 antisense oligonucleotide | – | Phase 2 | Hypertriglyceridemia | Nov 2026 |
| MAR002 | – | Phase 2 | Acromegaly | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07195175 | MAR002 | Phase 1 | Acromegaly | Metabolic and endocrine | Jul 2026 |
| NCT07199309 | MAR001 | Phase 2 | Hypertriglyceridemia | Metabolic and endocrine | Nov 2026 |
| NCT07641179 | MAR002 | Phase 2 | Acromegaly | Metabolic and endocrine | Aug 2027 |
| NCT07028749 | MAR001 | Phase 2 | Hypertriglyceridemia | Metabolic and endocrine | Nov 2027 |
No annotated target.
–
Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.